Abstract
Background
Biosynthetic meshes afford the cost advantages of being made from fully synthetic material, but are also biodegradable, making them a versatile option that can be used in both clean and contaminated cases. The aim of this study is to evaluate the safety profile and long-term outcomes of using GORE BIO-A (BIO-A) as an adjunct to abdominal wall reconstruction in all wound classes.
Methods
A retrospective review identified patients undergoing abdominal hernia repair using BIO-A from October 2008 to June 2018. The primary outcome was hernia recurrence rate. Only patients with at least 6-month follow-up were included when looking at recurrence rates. Secondary outcomes included 30-day morbidity categorized according to CDC Surgical Site Infection Criteria, return to operating/procedure room (RTOR), 30-day readmission, length of stay (LOS), and mortality.
Results
A total of 207 patients were identified, CDC Wound Classification breakdown was 127 (61.4%), 41 (19.8%), 14 (6.8%), and 25 (12.1%) for wound classes I, II, III, and IV, respectively. Median follow-up was 55.4 months (range 0.2–162.4). Overall recurrence rate was 17.4%. Contaminated cases experienced higher recurrence rates (28.8% versus 10.4%, p = 0.002) at a mean follow up of 46.9 and 60.8 months for contaminated and clean patients, respectively. Recurrent patients had higher BMI (32.4 versus 28.4 kg/m2, p = 0.0011), larger hernias (162.2 versus 106.7 cm2, p = 0.10), higher LOS (11.1 versus 5.6 days, p = 0.0051), and higher RTOR rates (16.7% versus 5.6%, p = 0.053). 51 (24.5%) patients experienced some morbidity, including 19 (9.2%) surgical site occurences, 7 (3.4%) superficial surgical site infections, 16 (7.7%) deep surgical site infections, and 1 (0.5%) organ space infection.
Conclusion
This study affirms the use of biosynthetic mesh as a cost-effective alternative in all wound classifications, yielding good outcomes, limited long-term complications, and low recurrence.
rates.
Similar content being viewed by others
References
Park AE, Roth JS, Kavic SM (2006) Abdominal wall hernia. Curr Probl Surg 43(5):326–375. https://doi.org/10.1067/j.cpsurg.2006.02.004
Breuing K, Butler CE, Ferzoco S et al (2010) Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. Surgery 148(3):544–558. https://doi.org/10.1016/j.surg.2010.01.008
Rosen MJ, Krpata DM, Ermlich B, Blatnik JA (2013) A 5-year clinical experience with single-staged repairs of infected and contaminated abdominal wall defects utilizing biologic mesh. Ann Surg 257(6):991–996. https://doi.org/10.1097/SLA.0b013e3182849871
Rosen MJ, Krpata DM, Petro CC et al (2022) Biologic vs synthetic mesh for single-stage repair of contaminated ventral hernias: a randomized clinical trial. JAMA Surg 157(4):293–301. https://doi.org/10.1001/jamasurg.2021.6902
Kim H, Bruen K, Vargo D (2006) Acellular dermal matrix in the management of high-risk abdominal wall defects. Am J Surg 192(6):705–709. https://doi.org/10.1016/j.amjsurg.2006.09.003
Reid CM, Jacobsen GR (2018) A current review of hybrid meshes in abdominal wall reconstruction. Plast Reconstr Surg 142(3 Suppl):92s–96s. https://doi.org/10.1097/prs.0000000000004860
Pierides GA, Paajanen HE, Vironen JH (2016) Factors predicting chronic pain after open mesh based inguinal hernia repair: a prospective cohort study. Int J Surg 29:165–170. https://doi.org/10.1016/j.ijsu.2016.03.061
Aasvang EK, Kehlet H (2009) The effect of mesh removal and selective neurectomy on persistent postherniotomy pain. Ann Surg 249(2):327–334. https://doi.org/10.1097/SLA.0b013e31818eec49
Rosen MJ, Bauer JJ, Harmaty M et al (2017) Multicenter, prospective, longitudinal study of the recurrence, surgical site infection, and quality of life after contaminated ventral hernia repair using biosynthetic absorbable mesh: The COBRA study. Ann Surg 265(1):205–211. https://doi.org/10.1097/sla.0000000000001601
Burger JW, Luijendijk RW, Hop WC, Halm JA, Verdaasdonk EG, Jeekel J (2004) Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. Ann Surg 240(4):578–583. https://doi.org/10.1097/01.sla.0000141193.08524.e7
Luijendijk RW, Hop WC, van den Tol MP et al (2000) A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med 343(6):392–398. https://doi.org/10.1056/nejm200008103430603
Kokotovic D, Bisgaard T, Helgstrand F (2016) Long-term recurrence and complications associated with elective incisional hernia repair. JAMA 316(15):1575–1582. https://doi.org/10.1001/jama.2016.15217
Harris HW, Primus F, Young C et al (2021) Preventing recurrence in clean and contaminated hernias using biologic versus synthetic mesh in ventral hernia repair: the PRICE randomized clinical trial. Ann Surg 273(4):648–655. https://doi.org/10.1097/sla.0000000000004336
Peralta R, Latifi R (2012) Long-term outcomes of abdominal wall reconstruction. What are the real numbers? World J Surg 36(3):534–538. https://doi.org/10.1007/s00268-012-1454-y
Ferzoco SJ (2013) A systematic review of outcomes following repair of complex ventral incisional hernias with biologic mesh. Int Surg Oct-Dec 98(4):399–408. https://doi.org/10.9738/intsurg-d-12-00002.1
Huntington CR, Cox TC, Blair LJ et al (2016) Biologic mesh in ventral hernia repair: outcomes, recurrence, and charge analysis. Surgery 160(6):1517–1527. https://doi.org/10.1016/j.surg.2016.07.008
Basta MN, Fischer JP, Kovach SJ (2015) Assessing complications and cost-utilization in ventral hernia repair utilizing biologic mesh in a bridged underlay technique. Am J Surg 209(4):695–702. https://doi.org/10.1016/j.amjsurg.2014.04.017
Holihan JL, Alawadi Z, Martindale RG et al (2015) Adverse events after ventral hernia repair: the vicious cycle of complications. J Am Coll Surg 221(2):478–485. https://doi.org/10.1016/j.jamcollsurg.2015.04.026
Kanitra JJ, Hess AL, Haan PS, Anderson CI, Kavuturu S (2019) Hernia recurrence and infection rate in elective complex abdominal wall repair using biologic mesh. BMC Surg 19(1):174. https://doi.org/10.1186/s12893-019-0640-3
Shao JM, Ayuso SA, Deerenberg EB et al (2022) Biologic mesh is non-inferior to synthetic mesh in CDC class 1 & 2 open abdominal wall reconstruction. Am J Surg 223(2):375–379. https://doi.org/10.1016/j.amjsurg.2021.05.019
Fischer JP, Basta MN, Krishnan NM, Wink JD, Kovach SJ (2016) A cost-utility assessment of mesh selection in clean-contaminated ventral hernia repair. Plast Reconstr Surg 137(2):647–659. https://doi.org/10.1097/01.prs.0000475775.44891.56
Jacobsen GR, Chao JJ (2018) Clinical use of GORE BIO-a tissue reinforcement in ventral hernia repair using the components separation technique. W. L. Gore & Associates, Newark
Rognoni C, Bassi UA, Cataldo M et al (2018) Budget impact analysis of a biosynthetic mesh for incisional hernia repair. Clin Ther 40(11):1830-1844.e4. https://doi.org/10.1016/j.clinthera.2018.09.003
Schneeberger S, Phillips S, Huang LC, Pierce RA, Etemad SA, Poulose BK (2019) Cost-utility analysis of biologic and biosynthetic mesh in ventral hernia repair: when are they worth it? J Am Coll Surg 228(1):66–71. https://doi.org/10.1016/j.jamcollsurg.2018.10.009
Nguyen MT, Berger RL, Hicks SC et al (2014) Comparison of outcomes of synthetic mesh vs suture repair of elective primary ventral herniorrhaphy: a systematic review and meta-analysis. JAMA Surg 149(5):415–421. https://doi.org/10.1001/jamasurg.2013.5014
Choi JJ, Palaniappa NC, Dallas KB, Rudich TB, Colon MJ, Divino CM (2012) Use of mesh during ventral hernia repair in clean-contaminated and contaminated cases: outcomes of 33,832 cases. Ann Surg 255(1):176–180. https://doi.org/10.1097/SLA.0b013e31822518e6
East B, Hill S, Dames N et al (2021) Patient views around their hernia surgery: a worldwide online survey promoted through social media. Front Surg 8:769938. https://doi.org/10.3389/fsurg.2021.769938
Funding
No funding information to disclose for this project.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Broderick is a consultant for Stryker Corporation. Sandler is a consultant for Intuitive Surgical and Boston Scientific. Horgan is a consultant for Stryker Corporation, Intuitive Surgical, Fortimedix Surgical, and Alume Biosciences. Jacobsen is a consultant for Gore Medical and Viacyte. Estella Y. Huang, Graham J. Spurzem, Jonathan Z. Li, Rachel R. Blitzer, Joslin N. Cheverie have no disclosures.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Huang, E.Y., Broderick, R.C., Spurzem, G.J. et al. Long-term outcomes of PGA-TMC absorbable synthetic scaffold in both clean and contaminated ventral hernia repairs. Surg Endosc 38, 2231–2239 (2024). https://doi.org/10.1007/s00464-024-10777-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-024-10777-z